Xeris Biopharma’s core business model is focused on niche specialty pharmaceuticals targeting rare endocrine diseases, with revenue driven primarily by Recorlev’s rapid market penetration and steady growth of Gvoke. The company benefits from proprietary delivery technologies and a focused commercia…
Xeris Biopharma (XERS) Q4 2024: Recorlev Revenue Surges 131%, Driving 30% Growth Outlook for 2025
Xeris Biopharma’s fourth quarter capped a year of robust revenue growth led by Recorlev, positioning the company for a transformative 2025 with over 30% projected sales growth. The company’s expanding commercial footprint and pipeline progress underpin sustained momentum, while adjusted EBITDA turned positive in Q4, signaling improving financial health. Investors should monitor execution on Recorlev’s market expansion and XP-8121 development as key growth drivers.
Summary
- Commercial Momentum Strengthens: Recorlev’s rapid patient adoption accelerates revenue and market presence.
- Financial Transformation Underway: Positive adjusted EBITDA and disciplined expense management mark operational leverage.
- Pipeline Advancement Aligns with Core Strategy: XP-8121 development leverages existing endocrinology infrastructure for future growth.
Business Overview
Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and marketing innovative therapies for rare and chronic diseases. Its revenue primarily derives from three marketed products: Recorlev, a treatment for endogenous Cushing’s syndrome; Gvoke, a ready-to-use liquid glucagon for severe hypoglycemia; and Keveyis, a therapy for primary periodic paralysis. The company also generates royalty and contract revenue from its technology platforms and partners, while advancing a pipeline led by XP-8121, a Phase 3-ready subcutaneous treatment for hypothyroidism.
Performance Analysis
The fourth quarter of 2024 marked a significant inflection point for Xeris with total revenue reaching $60.1 million, a 35% increase year-over-year, driven predominantly by a 131% surge in Recorlev revenue to $22.6 million. This growth reflects a 123% increase in patients on therapy compared to the prior year, highlighting successful market penetration and patient acquisition efforts. Gvoke continued its steady trajectory with 25% revenue growth to $23.3 million, supported by an 18% rise in prescriptions. Keveyis experienced a 21% revenue decline, stabilizing patient counts but indicating challenges in sustaining growth.
Gross margin improved modestly to 84% in Q4, aided by a favorable product mix despite prior capacity expansion costs for Gvoke. Operating expenses increased moderately, with SG&A up 7% driven by investments in Recorlev’s commercial expansion, while R&D remained flat sequentially, reflecting focused pipeline spending. The company reported a net loss of $5.1 million but delivered adjusted EBITDA of $8.3 million, its first positive quarterly result, signaling operational leverage and financial discipline. Cash generation of $2 million in the quarter strengthened the balance sheet, ending with $71.6 million in cash and equivalents.
- Revenue Growth Concentration: Recorlev’s rapid adoption is the primary driver of total revenue expansion, doubling year-over-year.
- Margin and Expense Dynamics: Favorable product mix supports gross margin improvement despite ongoing capacity investments.
- Profitability Inflection: Positive adjusted EBITDA in Q4 marks a shift toward sustainable profitability amid growth.
This performance underscores Xeris’s transition from growth at any cost to a balanced model emphasizing financial health and scalable commercial execution.
Executive Commentary
"The continued momentum of our commercial business, our exciting pipeline, along with our unrelenting focus on execution will enable Xeris to create even more value for patients and shareholders."
John Shannon, CEO
"Xeris has never been financially stronger. Record quarterly revenue exceeding $60 million drove positive cash flow of $2 million in the fourth quarter and generated Adjusted EBITDA of over $8 million."
Steven M. Pieper, CFO
Strategic Positioning
1. Accelerating Recorlev Market Penetration
Recorlev is rapidly becoming Xeris’s flagship product, benefiting from targeted investments that expanded the commercial organization by 50% in 2024. The company is capitalizing on an expanding hypercortisolemia market, driven by increased screening and diagnosis of cortisol-related disorders. Management highlighted both growth in new prescribers and increased patient volumes from existing physicians, signaling deepening market penetration and physician comfort with the therapy.
2. Sustained Growth in Gvoke with Large Untapped Market
Gvoke’s growth remains steady and predictable, with a 24% increase in annual revenue and a 23% rise in prescriptions. Despite a large addressable market of approximately 15 million insulin or sulfonylurea users, only about 1 million currently have prescriptions for life-saving glucagon therapy. Xeris is actively driving awareness and compliance with updated medical guidelines, supported by a multi-year strategic partnership with the American Diabetes Association to increase adoption.
3. Keveyis Stability Amid Market Challenges
Keveyis revenue declined 13% year-over-year, primarily due to reduced product shipments, but patient counts remained stable. The company continues efforts to identify new patients with primary periodic paralysis and maintain therapy adherence. While reimbursement pressures persist, management expects patient demand to hold steady in 2025.
4. Pipeline Development Leveraging Commercial Infrastructure
XP-8121, a once-weekly subcutaneous treatment for hypothyroidism, represents a significant growth opportunity with limited innovation in the market for decades. Xeris is progressing through Phase 3 readiness, with ongoing FDA discussions to align on clinical and regulatory pathways. The product’s fit within Xeris’s existing endocrinology sales and support infrastructure offers potential for streamlined commercialization and cost efficiencies.
5. Financial Discipline and Transparency
Xeris’s first positive adjusted EBITDA quarter and disciplined expense growth reflect a maturing business model balancing growth and financial sustainability. Management’s commitment to maintaining a healthy balance sheet without shareholder dilution signals confidence in organic growth and capital allocation priorities.
Key Considerations
Xeris Biopharma’s fourth quarter and full-year results reveal a company transitioning into a more financially sustainable phase while aggressively expanding its commercial footprint. The following considerations are critical for investors:
- Market Expansion Opportunity: The rapid growth in Recorlev patients and prescriptions indicates a sizable and expanding market for hypercortisolemia treatment, supported by increased diagnosis and guideline awareness.
- Commercial Execution Leverage: Investments in sales force expansion and patient support are beginning to yield results, but incremental spending decisions will require monitoring as market dynamics evolve.
- Pipeline Timing and Risk: XP-8121’s Phase 3 initiation is expected in 2026, with 2025 focused on readiness; clinical and regulatory risks remain inherent to development-stage assets.
- Financial Outlook Confidence: Positive adjusted EBITDA and cash generation suggest improving operational efficiency, but sustaining this trend depends on continued revenue growth and expense control.
- Competitive and Market Dynamics: The presence of competitors expanding sales and marketing in the hypercortisolemia space underscores the need for Xeris to maintain differentiation and market share gains.
Risks
Key risks include potential reimbursement pressures, particularly for Keveyis, uncertainties in patient adoption rates beyond initial growth phases, and the inherent clinical and regulatory risks associated with XP-8121’s development. Market competition and changes in managed care policies could also impact revenue trajectories. Additionally, first quarter payer resets may cause temporary revenue fluctuations, requiring careful monitoring.
Forward Outlook
For the first quarter of 2025, Xeris anticipates continued strong patient demand for Recorlev, with growth rates expected to sustain or exceed the second half of 2024, albeit with typical first quarter payer reset impacts. Gvoke prescription growth is projected to remain steady, while Keveyis is expected to hold patient demand despite pricing pressures.
- Total revenue guidance for 2025 is $255 million to $275 million, representing over 30% year-over-year growth at the midpoint.
- Adjusted EBITDA is expected to remain positive throughout 2025, reflecting operational leverage and disciplined expense management.
Management emphasized reinvestment in Recorlev commercial efforts and incremental R&D spending for XP-8121, with more substantial clinical trial costs anticipated in 2026. Partner revenue is expected to remain consistent with recent years.
Takeaways
Xeris Biopharma is entering a pivotal phase characterized by accelerating commercial growth and improving financial metrics, driven by its flagship product Recorlev and a robust pipeline candidate.
- Commercial Growth Engine: Recorlev’s 131% revenue surge and expanding patient base underpin a strong growth trajectory, supported by targeted sales force expansion and market awareness efforts.
- Financial Maturation: Positive adjusted EBITDA and cash flow generation in Q4 2024 mark a transition toward profitability, enabled by favorable product mix and disciplined expense control.
- Pipeline Synergies: XP-8121’s development aligns strategically with existing endocrinology assets, offering potential for efficient commercialization and incremental revenue streams beyond 2025.
Conclusion
Xeris Biopharma’s Q4 2024 results confirm its evolution from a growth-focused biopharma to a financially disciplined commercial enterprise. With Recorlev gaining rapid market traction and a promising pipeline advancing, the company is well-positioned for a transformative 2025 marked by substantial revenue growth and improving profitability.
Industry Read-Through
Xeris’s strong Recorlev growth amid expanding hypercortisolemia awareness highlights the importance of education and diagnosis in rare endocrine disorders. The company’s ability to leverage targeted commercial investments and partnerships may serve as a model for biopharma firms seeking to scale orphan drug markets sustainably. Additionally, the positive adjusted EBITDA milestone underscores a broader industry trend where specialty biopharma companies are balancing innovation with financial discipline to achieve sustainable growth. Investors and competitors should watch how Xeris manages pipeline progression alongside commercial expansion as a bellwether for the sector’s maturation.